Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

16,060 11,138

Inventory subject to return 445 2,560

Prepaid expenses and other 539 589

Total current assets 21,876 27,885

Long-term assets:

Property and equipment, net 917 1,170

Intangible assets, net 2,500 1,633

Other assets - 19

Total assets $25,293 $30,707

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:

Accounts payable $1,413 $1,277

Accrued expenses 851 837

Accrued chargebacks and administrative fees 385 1,317

Deferred revenue 955 5,373

Notes payable 15,615 11,698

Total current liabilities 19,219 20,502

Other long-term liability 219 -

Total liabilities 19,438 20,502

Total redeemable convertible preferred stock 35,863 -

Total stockholders' equity (deficit) (30,008) 10,205

Total liabilities and stockholders' equity (deficit) $25,293 $30,707

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

sephraim@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... September 18, 2014 OMICS Group ... globe to participate in the ‘Open Access Week’ ... to OMICS Group Pharma Journals from ... of the fastest emerging Sciences, accelerating with a ... services across the globe. The industry is gearing ...
(Date:9/18/2014)... pretty expensive. Now a team led by an engineer ... of designs that will let scientists slash the cost ... pump. , Syringe pumps are used to dispatch precise ... chemicals in a reaction. They can also cost hundreds ... his team of Michigan Tech students published the library ...
(Date:9/18/2014)... Just about everything we touch in the course ... detergent - even medicines, rely on the chemical ... by-products, minerals and farm products into valuable chemicals ... , QUT scientist Dr Sarina Sarina, who achieved ... production process at ambient temperature using light instead ...
Breaking Biology Technology:Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2Using solar energy to turn raw materials into ingredients for every day life 2
... BioLife,s Proprietary, Next Generation, Biopreservation, Media Resulted in Increased Yield ... ... Cells, BOTHELL, Wash., Oct. 24 ... of,proprietary hypothermic storage and cryopreservation media products for,cells, tissues, and organs, ...
... Corp. (Other,OTC: IDTA.PK) released today the Jant Pharmacal ... and Oversees markets., - The strategic partnership ... continues, has resulted in increasing market,penetration over the ... sales,have increased significantly in the United States with ...
... Notice of Allowance of European Patent Application Covering Its Core ... Product Applications Protection Rights to All Cytokine ... ... GenOdyssee (GO), a biotechnology,company dedicated to the discovery and development of ...
Cached Biology Technology:BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 2BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 3BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 4International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 2GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 3GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 4
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (MGH) researchers have developed a new type of miniature ... expand the application of minimally invasive diagnostic and therapeutic ... the team from the Wellman Center for Photomedicine at ... its use in a mouse model. , ...
... 4 cases of botulism following cosmetic injections to the ... unlicensed preparation that resulted in toxin levels up to ... a report in the November 22/29 issue of JAMA. ... by the toxins of the spore-forming bacterium Clostridium botulinum ...
... collaborating institutions report in this week's Science a ... 2.8 kilometers below Earth's surface. Think that's weird? ... water molecules to useable energy. , The ... the three-dimensional shell that encompasses all planetary life. ...
Cached Biology News:Three-dimensional, miniature endoscope opens new diagnostic possibilities 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3
Request Info...
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
RNase-Free DNase 50 l...
Biology Products: